Long-term effects of antipsychotics on mortality in patients with schizophrenia: a systematic review and meta-analysis

Detalhes bibliográficos
Autor(a) principal: Jia,Ningning
Data de Publicação: 2022
Outros Autores: Li,Zhijun, Li,Xinwei, Jin,Mengdi, Liu,Yane, Cui,Xingyao, Hu,Guoyan, Liu,Yang, He,Yang, Yu,Qiong
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Brazilian Journal of Psychiatry (São Paulo. 1999. Online)
Texto Completo: http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1516-44462022000600664
Resumo: Objective: To gather current evidence on the impact of antipsychotics on long-term mortality in patients with schizophrenia. Methods: We systematically searched for articles in Embase, PubMed, and PsycINFO reporting the long-term mortality (follow-up > 1 year) of patients with schizophrenia who were using any antipsychotics. We then conducted multiple meta-analyses to determine differences in long-term mortality between different types of antipsychotics. Results: We identified 45 articles that provided unadjusted long-term mortality rates, including 46,171 deaths during 2,394,911 person-years. The pooled mortality rate was 9.9 (95%CI = 7.4-12.7) per 1,000 person-years. The unadjusted crude mortality rate of antipsychotic drug users was lower than that of non-users (risk ratio [RR] = 0.546, 95%CI = 0.480-0.621), first-generation antipsychotics caused higher all-cause mortality than second-generation antipsychotics (RR = 1.485, 95%CI = 1.361-1.620), and polypharmacy had better effects than monotherapy on long-term mortality (RR = 0.796, 95%CI = 0.689-0.921). As for the causes of death, heart disease and cardiovascular disease ranked highest among cause-specific mortality (5.6 per 1,000 person-years). Conclusion: Since antipsychotics had a beneficial effect on long-term mortality in schizophrenia, greater precaution should be taken with patients who do not take them. However, since disease severity, comorbidities, and other confounding factors cannot be fully controlled, further research and verification are needed.
id ABP-1_b74f8e75e45f213f849537898b864ed7
oai_identifier_str oai:scielo:S1516-44462022000600664
network_acronym_str ABP-1
network_name_str Brazilian Journal of Psychiatry (São Paulo. 1999. Online)
repository_id_str
spelling Long-term effects of antipsychotics on mortality in patients with schizophrenia: a systematic review and meta-analysisSchizophreniaantipsychoticslong-termmortality Objective: To gather current evidence on the impact of antipsychotics on long-term mortality in patients with schizophrenia. Methods: We systematically searched for articles in Embase, PubMed, and PsycINFO reporting the long-term mortality (follow-up > 1 year) of patients with schizophrenia who were using any antipsychotics. We then conducted multiple meta-analyses to determine differences in long-term mortality between different types of antipsychotics. Results: We identified 45 articles that provided unadjusted long-term mortality rates, including 46,171 deaths during 2,394,911 person-years. The pooled mortality rate was 9.9 (95%CI = 7.4-12.7) per 1,000 person-years. The unadjusted crude mortality rate of antipsychotic drug users was lower than that of non-users (risk ratio [RR] = 0.546, 95%CI = 0.480-0.621), first-generation antipsychotics caused higher all-cause mortality than second-generation antipsychotics (RR = 1.485, 95%CI = 1.361-1.620), and polypharmacy had better effects than monotherapy on long-term mortality (RR = 0.796, 95%CI = 0.689-0.921). As for the causes of death, heart disease and cardiovascular disease ranked highest among cause-specific mortality (5.6 per 1,000 person-years). Conclusion: Since antipsychotics had a beneficial effect on long-term mortality in schizophrenia, greater precaution should be taken with patients who do not take them. However, since disease severity, comorbidities, and other confounding factors cannot be fully controlled, further research and verification are needed.Associação Brasileira de Psiquiatria2022-12-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersiontext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S1516-44462022000600664Brazilian Journal of Psychiatry v.44 n.6 2022reponame:Brazilian Journal of Psychiatry (São Paulo. 1999. Online)instname:Associação Brasileira de Psiquiatria (ABP)instacron:ABP10.47626/1516-4446-2021-2306info:eu-repo/semantics/openAccessJia,NingningLi,ZhijunLi,XinweiJin,MengdiLiu,YaneCui,XingyaoHu,GuoyanLiu,YangHe,YangYu,Qiongeng2022-12-14T00:00:00Zoai:scielo:S1516-44462022000600664Revistahttp://www.bjp.org.br/ahead_of_print.asphttps://old.scielo.br/oai/scielo-oai.php||rbp@abpbrasil.org.br1809-452X1516-4446opendoar:2022-12-14T00:00Brazilian Journal of Psychiatry (São Paulo. 1999. Online) - Associação Brasileira de Psiquiatria (ABP)false
dc.title.none.fl_str_mv Long-term effects of antipsychotics on mortality in patients with schizophrenia: a systematic review and meta-analysis
title Long-term effects of antipsychotics on mortality in patients with schizophrenia: a systematic review and meta-analysis
spellingShingle Long-term effects of antipsychotics on mortality in patients with schizophrenia: a systematic review and meta-analysis
Jia,Ningning
Schizophrenia
antipsychotics
long-term
mortality
title_short Long-term effects of antipsychotics on mortality in patients with schizophrenia: a systematic review and meta-analysis
title_full Long-term effects of antipsychotics on mortality in patients with schizophrenia: a systematic review and meta-analysis
title_fullStr Long-term effects of antipsychotics on mortality in patients with schizophrenia: a systematic review and meta-analysis
title_full_unstemmed Long-term effects of antipsychotics on mortality in patients with schizophrenia: a systematic review and meta-analysis
title_sort Long-term effects of antipsychotics on mortality in patients with schizophrenia: a systematic review and meta-analysis
author Jia,Ningning
author_facet Jia,Ningning
Li,Zhijun
Li,Xinwei
Jin,Mengdi
Liu,Yane
Cui,Xingyao
Hu,Guoyan
Liu,Yang
He,Yang
Yu,Qiong
author_role author
author2 Li,Zhijun
Li,Xinwei
Jin,Mengdi
Liu,Yane
Cui,Xingyao
Hu,Guoyan
Liu,Yang
He,Yang
Yu,Qiong
author2_role author
author
author
author
author
author
author
author
author
dc.contributor.author.fl_str_mv Jia,Ningning
Li,Zhijun
Li,Xinwei
Jin,Mengdi
Liu,Yane
Cui,Xingyao
Hu,Guoyan
Liu,Yang
He,Yang
Yu,Qiong
dc.subject.por.fl_str_mv Schizophrenia
antipsychotics
long-term
mortality
topic Schizophrenia
antipsychotics
long-term
mortality
description Objective: To gather current evidence on the impact of antipsychotics on long-term mortality in patients with schizophrenia. Methods: We systematically searched for articles in Embase, PubMed, and PsycINFO reporting the long-term mortality (follow-up > 1 year) of patients with schizophrenia who were using any antipsychotics. We then conducted multiple meta-analyses to determine differences in long-term mortality between different types of antipsychotics. Results: We identified 45 articles that provided unadjusted long-term mortality rates, including 46,171 deaths during 2,394,911 person-years. The pooled mortality rate was 9.9 (95%CI = 7.4-12.7) per 1,000 person-years. The unadjusted crude mortality rate of antipsychotic drug users was lower than that of non-users (risk ratio [RR] = 0.546, 95%CI = 0.480-0.621), first-generation antipsychotics caused higher all-cause mortality than second-generation antipsychotics (RR = 1.485, 95%CI = 1.361-1.620), and polypharmacy had better effects than monotherapy on long-term mortality (RR = 0.796, 95%CI = 0.689-0.921). As for the causes of death, heart disease and cardiovascular disease ranked highest among cause-specific mortality (5.6 per 1,000 person-years). Conclusion: Since antipsychotics had a beneficial effect on long-term mortality in schizophrenia, greater precaution should be taken with patients who do not take them. However, since disease severity, comorbidities, and other confounding factors cannot be fully controlled, further research and verification are needed.
publishDate 2022
dc.date.none.fl_str_mv 2022-12-01
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1516-44462022000600664
url http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1516-44462022000600664
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv 10.47626/1516-4446-2021-2306
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv text/html
dc.publisher.none.fl_str_mv Associação Brasileira de Psiquiatria
publisher.none.fl_str_mv Associação Brasileira de Psiquiatria
dc.source.none.fl_str_mv Brazilian Journal of Psychiatry v.44 n.6 2022
reponame:Brazilian Journal of Psychiatry (São Paulo. 1999. Online)
instname:Associação Brasileira de Psiquiatria (ABP)
instacron:ABP
instname_str Associação Brasileira de Psiquiatria (ABP)
instacron_str ABP
institution ABP
reponame_str Brazilian Journal of Psychiatry (São Paulo. 1999. Online)
collection Brazilian Journal of Psychiatry (São Paulo. 1999. Online)
repository.name.fl_str_mv Brazilian Journal of Psychiatry (São Paulo. 1999. Online) - Associação Brasileira de Psiquiatria (ABP)
repository.mail.fl_str_mv ||rbp@abpbrasil.org.br
_version_ 1754212560873193472